{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"98"}],"title":"CR or sCR"},{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"60"}],"title":"VGPR or nCR"},{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"50"}],"title":"Worse than VGPR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"209"},{"groupId":"OG002","value":"208"}],"units":"Participants"}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"117"},{"groupId":"OG002","value":"93"}],"title":"CR or sCR"},{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"41"}],"title":"VGPR or nCR"},{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"26"}],"title":"Worse than VGPR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"160"}],"units":"Participants"}],"title":"2 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"The number of participants with very good partial response (VGPR) or better \\[complete response (CR), near CR (nCR), and stringent CR (sCR)\\] according to the International Uniform Response Criteria will be calculated. The \"Worse than VGPR\" group includes PR, stable disease, and progressive disease.\n\nsCR requires, in addition to CR: Normal free light chain ratio (FLC), Absence of clonal cells in bone marrow CR requires, in addition to nCR: Absence of the original monoclonal paraprotein (PPN), Disappearance of soft tissue plasmacytomas nCR is defined as: \\< 5% plasma cells in a bone marrow aspirate, No increase in lytic bone lesions VGPR requires: Serum or urine PPN not detectable on electrophoresis OR \\>=90% reduction in serum PPN plus urine PPN \\<100 mg/24hrs, \\>= 50% reduction in the level of serum monoclonal PPN or reduction in 24 hour urinary monoclonal PPN either \\>= 90% or to \\<200 mg/24 hours in light chain disease, \\>= 50% reduction in the size of soft tissue plasmacytomas","groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nlenalidomide, bortezomib and dexamethasone: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG002","title":"Lenalidomide Maintenance"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants that were evaluable for disease response were analyzed at each time point. Those who had died or experienced disease progression were excluded.","reportingStatus":"POSTED","timeFrame":"1 and 2 years post-randomization","title":"Number of Participants With Treatment Response","type":"SECONDARY","unitOfMeasure":"Participants"}